Monzr Al Malki, MD and Jeffery J. Auletta, MD discuss evaluating PTCy-based GVHD prophylaxis in hematologic malignancies.
Monzr M. Al Malki, MD
Advertisement
Monzr M. Al Malki, MD, is an associate professor in the Division of Leukemia and Hematopoietic Cell Transplantation, director of Unrelated Donor BMT Program, and director of Haploidentical Transplant Program at City of Hope.
Articles by Monzr M. Al Malki, MD
Monzr M. Al Malki, MD, discusses reducing relapse risk in patients undergoing haploidentical hematopoietic stem cell transplantation.
Monzr M. Al Malki, MD, discusses the potential use of TSC-100 and TSC-101 following allogeneic stem cell transplant in patients with AML, ALL or MDS.
Monzr M. Al Malki, MD, discusses outcomes with mismatched unrelated donor transplantation using post-transplant cyclophosphamide–based GVHD prophylaxis.
Advertisement
Latest Updated Articles
Drs Al Malki and Auletta on PTCy GVHD Prophylaxis in Patients With HLA-UUMDPublished: February 15th 2025 | Updated:
Dr Al Malki on Reducing Relapse Risk in Patients with MDS Undergoing Haplo-HSCTPublished: February 7th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5